4.4 Review

Genetic susceptibility factors for psoriatic arthritis

Journal

CURRENT OPINION IN RHEUMATOLOGY
Volume 22, Issue 2, Pages 152-156

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/BOR.0b013e32833669d2

Keywords

association; gene; psoriasis; psoriatic arthritis

Categories

Funding

  1. arthritis research campaign [17552]

Ask authors/readers for more resources

Purpose of review Psoriatic arthritis (PsA) has a large genetic component to its heritability, yet investigation into the genetic basis of the disease has lagged behind other rheumatic diseases mainly because of the difficulty in defining classification criteria that would accurately differentiate it from other forms of inflammatory arthritis. However, using a variety of approaches, some confirmed associations have now been identified with PsA susceptibility, making a review of these recent developments timely. Recent findings Family studies continue to suggest a large genetic contribution to PsA. Using a candidate gene approach, genes robustly confirmed to be associated with psoriasis vulgaris (PsV) have also been found to be associated with PsA (HLA-Cw*0602, IL23R, IL12B). There is less overlap reported with rheumatoid arthritis (RA) than PsA susceptibility loci but one report suggests that the AFF3 locus may be associated with both RA and PSA Summary Large, well powered genome-wide association studies are currently underway and should provide further insights into the cause of this common arthritic disease over the next few months. The bulk of evidence so far suggests that the genetic factors underlying PsV are also associated with PsA suggesting that future studies of PsV could include patients with PsA.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Dermatology

Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity

K. A. Bain, E. McDonald, F. Moffat, M. Tutino, M. Castelino, A. Barton, J. Cavanagh, U. Z. Ijaz, S. Siebert, I. B. McInnes, A. Astrand, S. Holmes, S. W. F. Milling

BRITISH JOURNAL OF DERMATOLOGY (2020)

Article Rheumatology

Adding value to real-world data: the role of biomarkers

Darren Plant, Anne Barton

RHEUMATOLOGY (2020)

Article Rheumatology

Long-term outcomes of patients who rate symptoms of rheumatoid arthritis as 'satisfactory'

James M. Gwinnutt, Kimme L. Hyrich, Mark Lunt, Anne Barton, Suzanne M. M. Verstappen

RHEUMATOLOGY (2020)

Article Genetics & Heredity

Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients

Stephanie F. Ling, Nisha Nair, Suzanne M. M. Verstappen, Anne Barton, Hans-Dieter Zucht, Petra Budde, Peter Schulz-Knappe, Darren Plant

PHARMACOGENOMICS JOURNAL (2020)

Article Rheumatology

Translating research into clinical practice: quality improvement to halve non-adherence to methotrexate

Anne Barton, Meghna Jani, Christine Bundy, James Bluett, Stephen McDonald, Brian Keevil, Faraz Dastagir, Melissa Aris, Ian Bruce, Pauline Ho, Eoghan McCarthy, Ellen Bruce, Ben Parker, Kimme Hyrich, Rachel Gorodkin

Summary: This study successfully reduced self-reported non-adherence to MTX from 24.7% to 7.4% through a series of interventions. Key factors for improvement included motivational interviewing and consistency in information delivery.

RHEUMATOLOGY (2021)

Article Rheumatology

Association between psoriatic disease and lifestyle factors and comorbidities: cross-sectional analysis and Mendelian randomization

Sizheng Steven Zhao, Eftychia Bellou, Suzanne M. M. Verstappen, Michael J. Cook, Jamie C. Sergeant, Richard B. Warren, Anne Barton, John Bowes

Summary: Observational and genetic evidence suggest that BMI and glycemic control are associated with increased risk of psoriatic disease, while psoriatic disease is associated with increased risk of coronary artery disease.

RHEUMATOLOGY (2023)

Review Genetics & Heredity

Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?

Philippa D. K. Curry, Andrew P. Morris, Anne Barton, James Bluett

Summary: Psoriatic arthritis is a chronic musculoskeletal disease that affects a significant proportion of psoriasis patients. The response to targeted therapies, such as TNF inhibitors, varies among patients. Researchers have been investigating potential genetic biomarkers for predicting drug response. Although several genetic variants have been reported to correlate with TNF inhibitor response, further validation and implementation into clinical practice are needed.

PHARMACOGENOMICS JOURNAL (2023)

Article Rheumatology

Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis

Ryan M. Hum, Pauline Ho, Nisha Nair, Meghna Jani, Ann W. Morgan, John D. Isaacs, Anthony G. Wilson, Kimme L. Hyrich, Darren Plant, Anne Barton

Summary: This study suggests that higher levels of TNF-a inhibitor serum drug levels (SDLs) are associated with good treatment response in fully adherent patients. Interventions to improve SDLs, such as encouraging adherence, may improve treatment response. The identified SDL cut-offs for adalimumab and certolizumab may be useful in clinical practice.

RHEUMATOLOGY (2023)

Review Biochemistry & Molecular Biology

Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis

Robert Gurke, Annika Bendes, John Bowes, Michaela Koehm, Richard M. Twyman, Anne Barton, Dirk Elewaut, Carl Goodyear, Lisa Hahnefeld, Rainer Hillenbrand, Ewan Hunter, Mark Ibberson, Vassilios Ioannidis, Sabine Kugler, Rik J. Lories, Eduard Resch, Stefan Rueping, Klaus Scholich, Jochen M. Schwenk, James C. Waddington, Phil Whitfield, Gerd Geisslinger, Oliver FitzGerald, Frank Behrens, Stephen R. Pennington

Summary: The definitive diagnosis and early treatment of immune-mediated inflammatory diseases (IMIDs) are challenging due to variable clinical manifestations. Psoriatic arthritis (PsA) is an example of such a disease. The detection of molecular biomarkers offers hope for the early diagnosis and treatment of PsA, but specific biomarkers are not yet available. By analyzing multi-omics data and integrating them with clinical assessment, it is possible to develop molecular profiles that improve the diagnosis and treatment outcomes of PsA patients.

BIOMEDICINES (2022)

Letter Rheumatology

Genetically proxied TYK2 inhibition is associated with reduced sarcoidosis susceptibility

Sizheng Steven Zhao, Anne Barton, John Bowes

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Biochemical Research Methods

BBmix: a Bayesian beta-binomial mixture model for accurate genotyping from RNA-sequencing

Elena Vigorito, Anne Barton, Costantino Pitzalis, Myles J. Lewis, Chris Wallace

Summary: In this study, a Bayesian beta-binomial mixture model (BBmix) is proposed for calling genotypes using RNA-Seq data, which can model specific biases in RNA-Seq. The benchmarking results show that BBmix generally outperforms competitors in genotype calling, with an increase of up to 1.4% in the accuracy of heterozygous calls. BBmix can be easily incorporated into standard genotype calling pipelines and the model parameters are generally transferable within datasets, making it possible to call genotypes in a large number of samples with less than 1 hour of learning.

BIOINFORMATICS (2023)

Letter Rheumatology

The Effect of COVID-19 on Medication Adherence in a Rheumatoid Arthritis (BRAGGSS) and Psoriatic Arthritis (OUTPASS) UK Cohort

Philippa D. K. Curry, Hector Chinoy, Meghna Jani, Darren Plant, Kimmie L. Hyrich, Ann W. Morgan, A. G. Wilson, John D. Isaacs, Andrew P. Morris, Anne Barton, James Bluett

JOURNAL OF RHEUMATOLOGY (2023)

Letter Rheumatology

HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritis

Chuan Fu Yap, Nisha Nair, Annick de Vries, Floris C. Loeff, Ann W. Morgan, John D. Isaacs, Anthony G. Wilson, Kimme L. Hyrich, Anne Barton, Darren Plant

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

A proteomics study of rheumatoid arthritis patients on etanercept identifies putative biomarkers associated with clinical outcome measures

Stephanie F. Ling, Chuan Fu Yap, Nisha Nair, James Bluett, Ann W. Morgan, John D. Isaacs, Anthony G. Wilson, Kimme L. Hyrich, Anne Barton, Darren Plant

Summary: This study aimed to identify proteomic biomarkers associated with clinical outcome measures in patients with rheumatoid arthritis (RA) starting biologic disease-modifying antirheumatic drugs (bDMARDs). Through SWATH-MS analysis of serum samples from RA patients before and after 3 months of treatment, ten proteins were found to be significantly associated with clinical outcome measures, and one of them was validated in an independent cohort.

RHEUMATOLOGY (2023)

Article Rheumatology

Expression quantitative trait loci analysis in rheumatoid arthritis identifies tissue specific variants associated with severity and outcome

Katriona Goldmann, Athina Spiliopoulou, Andrii Iakovliev, Darren Plant, Nisha Nair, Cankut Cubuk, Paul McKeigue, Michael R. Barnes, Anne Barton, Costantino Pitzalis, Myles J. Lewis

Summary: This study conducted expression quantitative trait locus (eQTL) analysis using RNA-Sequencing to explore the link between genetic variants and gene expression in rheumatoid arthritis (RA) patients. The analysis identified 898 eQTL genes in synovium and blood, with 232 genes in common. A specific eQTL at HLA-DPB2 was found to be associated with clinical severity and the lympho-myeloid pathotype.

ANNALS OF THE RHEUMATIC DISEASES (2023)

No Data Available